Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gottlieb: Real Risk Of Congressional Action If Anti-Competitive Actions Continue

Executive Summary

To remain shielded from political forces that could change incentives, pharmaceutical industry must adopt 'a certain set of values,' US FDA Commissioner says.

Related Content

Sharpless Calls For A Nimble, Flexible, More Efficient US FDA
Market Forces May Impact GDUFA III Talks
A US Drug Pricing Rebellion Looms, Analyst Says
Generic, Brand Industry Codes Of Ethics Share Common Themes, Language
Senate Health Care Cost Transparency Initiative Doesn't Mention Drug Pricing, But Likely Can't Avoid It
US FDA's Abram Makes The Case For 180-Day Exclusivity Reform
Sen. Cassidy Suggests Importing Generics From EU To Pressure US Prices
User Fee Bill Or Drug Pricing Bill? House Members Makes Both Cases
Drug Pricing 'Deeper Dive' Planned By Senate Cmte. As Industry Avoids First Blood
Complex Generics: Gottlieb Eyes FDA Policy Changes To Speed Approvals





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts